MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance.

• Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025.

Full Year 2026 Guidance

MaxCyte raises 2026 revenue guidance for core business revenue and SPL Program-related revenue:

• Full year revenue expected to be approximately $34 million, compared to prior guidance of $30 million to $32 million, consisting of:
  • Core business revenue of approximately $28 million, compared to prior guidance of $25 million to $27 million.
  • SPL Program-related revenue of approximately $6 million for the year, compared to prior guidance of approximately $5 million; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and approximately $2 million from commercial royalties.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.